Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD)
that leads to progressive and irreversible loss of visual function. Geographic atrophy is …

Purpose: To evaluate available rationale and outcomes of randomized trial results for
complement inhibition for geographic atrophy. Methods: Data from recently completed …

Purpose To analyze the prevalence, incidence, and clinical characteristics of eyes with
geographic atrophy (GA) in age-related macular degeneration (AMD), including clinical and …

Purpose To estimate the incidence, size, and growth rate of geographic atrophy (GA) during
5 years of follow-up among participants in the Comparison of Age-Related Macular …

Purpose To evaluate the growth of geographic atrophy (GA) during anti–vascular
endothelial growth factor (VEGF) therapy. Design Cohort within a clinical trial. Participants …

Purpose To determine whether emixustat hydrochloride (emixustat) reduces the rate of
enlargement of geographic atrophy (GA) compared with placebo in subjects with age …

Geographic atrophy (GA) of the retinal pigment epithelium (RPE) is a devastating
complication of age-related macular degeneration (AMD). GA may be classified as drusen …

Introduction Geographic atrophy (GA) is a progressive form of age-related macular
degeneration (AMD) that leads to severe visual impairment and central vision loss …

Importance Treatments for geographic atrophy (GA), a late stage of age-related macular
degeneration (AMD), are currently under development. Understanding the natural course is …

Worldwide, age-related macular degeneration (AMD) is a serious threat to vision loss in
individuals over 50 years of age with a pooled prevalence of approximately 9%. For 2020 …